<DOC>
	<DOCNO>NCT00343616</DOCNO>
	<brief_summary>RATIONALE : Studying cognitive function , thinking , attention , concentration , memory , postmenopausal woman receive hormone therapy breast cancer may help improve quality life ability plan treatment cancer . PURPOSE : This phase III trial study cognitive function postmenopausal woman breast cancer receive hormone therapy clinical trial IBCSG-1-98 .</brief_summary>
	<brief_title>Cognitive Function Postmenopausal Women With Breast Cancer Receiving Hormone Therapy Clinical Trial IBCSG-1-98</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare cognitive function postmenopausal woman breast cancer receive 5 year adjuvant tamoxifen v letrozole protocol IBCSG-1-98 . Secondary - Compare cognitive function patient receive single hormonal therapy 5 year vs receive hormonal therapy 3 year , previously receive alternate hormonal therapy 2 year . - Compare improvement cognitive function 1 year cessation adjuvant hormonal therapy . - Compare change cognitive function patient receive prior adjuvant chemotherapy v receive adjuvant chemotherapy . - Assess relationship objective subjective measure cognitive function , include specific cognitive domain . - Assess relationship cognitive function psychological distress , fatigue , quality life . OUTLINE : This longitudinal , multicenter study . Patients undergo cognitive function test complete self-reported questionnaire regard cognitive ability , quality life , fatigue , psychosocial status fifth year adjuvant hormonal therapy protocol IBCSG-1-98 sixth year* ( post randomization protocol IBCSG-1-98 ) ( i.e. , completion adjuvant hormonal therapy ) . NOTE : *Patients receive extend letrozole , hormone replacement therapy , endocrine therapy beyond 5 year undergo 6-year assessment . PROJECTED ACCRUAL : A total 148 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Enrolled protocol IBCSG198 Must fifth year study treatment ( i.e. , still receive tamoxifen letrozole ) No breast cancer recurrence second malignancy Patients receive 24Â½ year tamoxifen choose switch letrozole complete 5 year treatment protocol IBCSG198 eligible Hormone receptor status Estrogen receptor and/or progesterone receptorpositive tumor PATIENT CHARACTERISTICS : Female Postmenopausal PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>fatigue</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>